The Long-term Efficacy and Tolerability of the New Anti-inflammatory Agent Zaltoprofen in Rheumatoid Arthritis

References

• Armstrong C. P., Blower A. L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527, 5321. Armstrong C. P., Blower A. L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527, 532
   PubMed Web of Science ®Google Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A., Jr., Mitchell D. M., Neustadt D. H., Pinals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder G. G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315, 3242. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S., Medsger T. A., Jr., Mitchell D. M., Neustadt D. H., Pinals R. S., Schaller J. G., Sharp J. T., Wilder R. L., Hunder G. G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315, 324
   PubMed Web of Science ®Google Scholar
• Bijlsma A. The long-term efficacy and tolerability of voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. Scand. J Rheumatology 1978; 74–80, Suppl 223. Bijlsma A. The long-term efficacy and tolerability of voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis. Scand. J Rheumatology 1978; 74–80, Suppl 22
   Web of Science ®Google Scholar
• Burch F. X. Evaluation of the safety of isoxicam. Am. J. Med. 1985; 79: 28, 324. Burch F. X. Evaluation of the safety of isoxicam. Am. J. Med. 1985; 79: 28, 32
   PubMed Web of Science ®Google Scholar
• Ciccolunghi S. N., Chaudri H. A., Schubiger B. I. How long should long be? Long-term trials in rheumatic diseases. Annals Rheum. Dis. 1979; 38: 155, 1605. Ciccolunghi S. N., Chaudri H. A., Schubiger B. I. How long should long be? Long-term trials in rheumatic diseases. Annals Rheum. Dis. 1979; 38: 155, 160
   PubMed Web of Science ®Google Scholar
• Ciccolunghi S. N., Chaudri H. A., Schubiger B. I., Reddrop R. Report on a long-term tolerability study of up to two years with diclofenac sodium (voltaren). Scand. J. Rheumatology 1978; 86–96, Suppl 226. Ciccolunghi S. N., Chaudri H. A., Schubiger B. I., Reddrop R. Report on a long-term tolerability study of up to two years with diclofenac sodium (voltaren). Scand. J. Rheumatology 1978; 86–96, Suppl 22
   Web of Science ®Google Scholar
• Fries J. F., Miller S. R., Spitz P. W., Williams C. A., Hubert H. B., Bloch D. A. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647, 6557. Fries J. F., Miller S. R., Spitz P. W., Williams C. A., Hubert H. B., Bloch D. A. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647, 655
   PubMed Web of Science ®Google Scholar
• Graham D. Y., Smith J. L. Gastroduodenal complications of chronic NSAID therapy. Am. J. Gastroenterol. 1988; 83: 1081, 10848. Graham D. Y., Smith J. L. Gastroduodenal complications of chronic NSAID therapy. Am. J. Gastroenterol. 1988; 83: 1081, 1084
   PubMed Web of Science ®Google Scholar
• Griffin M. R., Ray W. A., Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann. Intern. Med. 1988; 109: 359, 3639. Griffin M. R., Ray W. A., Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann. Intern. Med. 1988; 109: 359, 363
   PubMed Web of Science ®Google Scholar
• Hatori M., Sakurai M., Kokubun S., Rijal K. P. Piroxicam suppositories in the treatment of osteoarthritis of the knee joint. Clin. Ther. 1990; 12: 227, 22910. Hatori M., Sakurai M., Kokubun S., Rijal K. P. Piroxicam suppositories in the treatment of osteoarthritis of the knee joint. Clin. Ther. 1990; 12: 227, 229
   PubMed Web of Science ®Google Scholar
• Hatori M., Sakurai M., Miyasaka Y. Clinical evaluation of BPAA patch in the treatment of extremity trauma. Conternp. Orthop. 1992; 24: 721, 72711. Hatori M., Sakurai M., Miyasaka Y. Clinical evaluation of BPAA patch in the treatment of extremity trauma. Conternp. Orthop. 1992; 24: 721, 727
   PubMedGoogle Scholar
• Hatori M., Kokubun S. Clinical evaluation of indomethacin-containing patches for osteoarthritis and extremity trauma. Cum Med. Res. Opin. 1997; 13: 511, 51512. Hatori M., Kokubun S. Clinical evaluation of indomethacin-containing patches for osteoarthritis and extremity trauma. Cum Med. Res. Opin. 1997; 13: 511, 515
   PubMed Web of Science ®Google Scholar
• Huskisson E. C., Ghozlan R., Kurthen R., Deigner F. L., Bluhmk E. A long-term study to evaluate the safety and efficiency of meloxicam therapy in patients with rheumatoid arthritis. Br. J Rheumatol. 1996; 35: 29–34, Suppl 113. Huskisson E. C., Ghozlan R., Kurthen R., Deigner F. L., Bluhmk E. A long-term study to evaluate the safety and efficiency of meloxicam therapy in patients with rheumatoid arthritis. Br. J Rheumatol. 1996; 35: 29–34, Suppl 1
   PubMedGoogle Scholar
• Ishizaki T., Kubota K., Echizen H., Horai Y., Chiba IK. Non-steroidal anti-inflammatory agent, phase 1 clinical trial with CN-100-single and repeated oral administration study. Rheumati 1992; 32: 12, 18, (In Japanese.)14. Ishizaki T., Kubota K., Echizen H., Horai Y., Chiba IK. Non-steroidal anti-inflammatory agent, phase 1 clinical trial with CN-100-single and repeated oral administration study. Rheumati 1992; 32: 12, 18, (In Japanese.)
   Google Scholar
• Jallad N. S., Cattan A., Weidler D. J. Efficacy of misoprostol in controlling indomethacin induced fecal blood loss in arthritic patients. J. Clin Pharmacol. 1993; 31: 376, 38115. Jallad N. S., Cattan A., Weidler D. J. Efficacy of misoprostol in controlling indomethacin induced fecal blood loss in arthritic patients. J. Clin Pharmacol. 1993; 31: 376, 381
   Web of Science ®Google Scholar
• Kameyama T., Nabeshima T., Yamada S., Sato M. Analgesic and antiinflammatory effects of 2–(10, 1l-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid in rat and mouse. Arzneim. -Forsch./ Drug Res. 1987; 37: 19, 2616. Kameyama T., Nabeshima T., Yamada S., Sato M. Analgesic and antiinflammatory effects of 2–(10, 1l-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid in rat and mouse. Arzneim. -Forsch./ Drug Res. 1987; 37: 19, 26
   PubMed Web of Science ®Google Scholar
• Lansbury J., Baier H. N., McCracken S. Statistical study of variation in systemic and articular indexes. Arth. Rheumat. 1962; 5: 445, 45617. Lansbury J., Baier H. N., McCracken S. Statistical study of variation in systemic and articular indexes. Arth. Rheumat. 1962; 5: 445, 456
   PubMed Web of Science ®Google Scholar
• Lockie L. M. Tolerability and efficacy of long-term daily administration of indomethacin for moderate to severe chronic arthritic disorders. Clin. Ther. 1986; 8: 398, 40518. Lockie L. M. Tolerability and efficacy of long-term daily administration of indomethacin for moderate to severe chronic arthritic disorders. Clin. Ther. 1986; 8: 398, 405
   PubMed Web of Science ®Google Scholar
• Pasero G., Marcolongo R., Serni U., Parnham M. J., Ferrer F. A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Curr Med. Res. Opin. 1995; 13: 305, 31519. Pasero G., Marcolongo R., Serni U., Parnham M. J., Ferrer F. A multi-centre, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac in the treatment of rheumatoid arthritis. Curr Med. Res. Opin. 1995; 13: 305, 315
   PubMed Web of Science ®Google Scholar
• Pincus T., Marcum S. B., Callahan L. F., Adams R. F., Barber J., Barth W. F., Gordon G. V., Huston J. W., Polk J. R., Whelton J. C., Brooks R. H. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J. Rheumatol. 1992; 19: 1874, 188420. Pincus T., Marcum S. B., Callahan L. F., Adams R. F., Barber J., Barth W. F., Gordon G. V., Huston J. W., Polk J. R., Whelton J. C., Brooks R. H. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J. Rheumatol. 1992; 19: 1874, 1884
   PubMed Web of Science ®Google Scholar
• Solomon L., Abrams G. Voltaren in the treatment of rheumatoid arthritis. S. Afr Med. J. 1974; 48: 949, 95221. Solomon L., Abrams G. Voltaren in the treatment of rheumatoid arthritis. S. Afr Med. J. 1974; 48: 949, 952
   PubMed Web of Science ®Google Scholar
• Steinbrocker O., Traeger C. H., Batterman R. C. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659, 66222. Steinbrocker O., Traeger C. H., Batterman R. C. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659, 662
   PubMed Web of Science ®Google Scholar
• Swift G. L., Arnold J., Williams G. T., Williams B. D., Rhodes J., Khan E. Risk of ulceration with long-term indomethacin: endoscopic and histological changes in upper gastro-intestinal mucosa. Digestion 1992; 53: 88, 9323. Swift G. L., Arnold J., Williams G. T., Williams B. D., Rhodes J., Khan E. Risk of ulceration with long-term indomethacin: endoscopic and histological changes in upper gastro-intestinal mucosa. Digestion 1992; 53: 88, 93
   PubMed Web of Science ®Google Scholar
• Tsurumi K., Kyuki K., Niwa M., Kokuba S., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. First communication: inhibitory effects on rat paw edema. Arzneim. -Forsck./Drug Res. 1986; 36: 1796, 180024. Tsurumi K., Kyuki K., Niwa M., Kokuba S., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. First communication: inhibitory effects on rat paw edema. Arzneim. -Forsck./Drug Res. 1986; 36: 1796, 1800
   PubMed Web of Science ®Google Scholar
• Tsurumi K., Icyuki K., Niwa M., Mibu H., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, ll-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Second communication: inhibitory effects on acute inflammation and prostaglandin-related reactions. Arzneim. -Forsch./Drug Res. 1986; 36: 1801, 180525. Tsurumi K., Icyuki K., Niwa M., Mibu H., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, ll-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Second communication: inhibitory effects on acute inflammation and prostaglandin-related reactions. Arzneim. -Forsch./Drug Res. 1986; 36: 1801, 1805
   PubMed Web of Science ®Google Scholar
• Tsurumi K., Mibu H., Okada K., Hasegawa J., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Third communication: inhibitory effects on leucocyte emigration and proliferation of granulation. Arzneim. Forsck./Drug Res. 1986; 36: 1806, 180926. Tsurumi K., Mibu H., Okada K., Hasegawa J., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Third communication: inhibitory effects on leucocyte emigration and proliferation of granulation. Arzneim. Forsck./Drug Res. 1986; 36: 1806, 1809
   PubMed Web of Science ®Google Scholar
• Tsurumi K., Kokuba S., Okada K., Yanagihara M., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Fourth communication: inhibitory effects on rat adjuvant arthritis. Arzneim. -Forsck./Drug Res. 1986; 36: 1810, 181727. Tsurumi K., Kokuba S., Okada K., Yanagihara M., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Fourth communication: inhibitory effects on rat adjuvant arthritis. Arzneim. -Forsck./Drug Res. 1986; 36: 1810, 1817
   PubMed Web of Science ®Google Scholar
• Tsurumi K., Kyuki K., Yanagihara M., Hasegawa J., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Fifth communication: antiplatelet effect of the drug and antiinflammatory effect of its main metabolite. Arzneim. -Forsck./Drug Res. 1986; 36: 1818, 182228. Tsurumi K., Kyuki K., Yanagihara M., Hasegawa J., Fujimura H. Pharmacological investigations of the new antiinflammatory agent 2–(10, 11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl) propionic acid. Fifth communication: antiplatelet effect of the drug and antiinflammatory effect of its main metabolite. Arzneim. -Forsck./Drug Res. 1986; 36: 1818, 1822
   PubMed Web of Science ®Google Scholar
• Wijnands M., van Riel P., van't Hof M., Gribnau F., van de Putte L. Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: A prospective drug survival study. J. Rheum. 1991; 18: 184, 18729. Wijnands M., van Riel P., van't Hof M., Gribnau F., van de Putte L. Longterm treatment with nonsteroidal antiinflammatory drugs in rheumatoid arthritis: A prospective drug survival study. J. Rheum. 1991; 18: 184, 187
   PubMed Web of Science ®Google Scholar
• Yoshizawa H., Nobunaga T. Early phase I1 clinical study of CN-100, new antiinflammatory agents on rheumatoid arthritis. Yakuri to Tiryo 1991; 19: 557, 569, (In Japanese.)30. Yoshizawa H., Nobunaga T. Early phase I1 clinical study of CN-100, new antiinflammatory agents on rheumatoid arthritis. Yakuri to Tiryo 1991; 19: 557, 569, (In Japanese.)
   Google Scholar